We are a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.
Our initial focus is on developing our novel and proprietary 5- Methoxy-N,N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment Resistant Depression, or TRD.
Our lead product candidate, GH001, is formulated for 5-MeO-DMT administration via a proprietary inhalation approach. With GH001, we have completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). Based on the observed clinical activity, where 87.5% of patients with TRD were brought into an ultra-rapid remission with our GH001 individualized single-day dosing regimen in the Phase 2 part of the trial, we believe that GH001 has potential to change the way TRD is treated today. Across the GH001 program, no serious adverse events have been reported and GH001 was well tolerated at the investigated single dose levels and in the individualized dosing regimen.
Our portfolio also includes GH002 and GH003, our proprietary injectable and intranasal 5-MeO-DMT product candidates.
Data Provided by Refinitiv. Minimum 15 minutes delayed.